Alnylam Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

CEO

Yvonne L. Greenstreet

CEOYvonne L. Greenstreet

Employees

2,500

Employees2,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2002

Founded2002

Employees

2,500

Employees2,500

ALNY Key Statistics

Market cap

32.19B

Market cap32.19B

Price-Earnings ratio

40.03

Price-Earnings ratio40.03

Dividend yield

—

Dividend yield—

Average volume

1.67M

Average volume1.67M

High today

$243.02

High today$243.02

Low today

$233.33

Low today$233.33

Open price

$233.88

Open price$233.88

Volume

1.61M

Volume1.61M

52 Week high

$495.55

52 Week high$495.55

52 Week low

$197.81

52 Week low$197.81

Stock Snapshot

Alnylam Pharmaceuticals(ALNY) stock is priced at $240.69, giving the company a market capitalization of 32.19B. It carries a P/E multiple of 40.03.

On 2026-09-01, Alnylam Pharmaceuticals(ALNY) stock moved within a range of $233.33 to $243.02. With shares now at $240.69, the stock is trading +3.2% above its intraday low and -1.0% below the session's peak.

Trading activity shows a volume of 1.61M, compared to an average daily volume of 1.67M.

The stock's 52-week range extends from a low of $197.81 to a high of $495.55.

ALNY News

Simply Wall St 7h

Expanded RNAi Cardio Data Might Change The Case For Investing In Alnylam Pharmaceuticals

Alnylam Pharmaceuticals recently presented new clinical and real-world data at the 2026 European Society of Cardiology Congress showing that its RNAi therapy AM...

TipRanks 20h

Alnylam Upgraded to Buy on Strong ATTR Cardiomyopathy Positioning and Amvuttra Mega-Blockbuster Potential

Analyst David Lebowitz of BMO Capital maintained a Buy rating on Alnylam Pharma, with a price target of $318.00. David Lebowitz has given his Buy rating due to...

TipRanks 22h

Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Alnylam Pharma, with a price target of $346.00. Tazeen...

Analyst ratings

75%

of 32 ratings

Buy

75%

Hold

25%

Sell

More ALNY News

TipRanks 1d

Alnylam announces new data at ESC Congress on AMVUTTRA

Alnylam (ALNY) Pharmaceuticals announced new data at the European Society of Cardiology, ESC, Congress 2026 demonstrating the strength of RNAi-powered silencing...

TipRanks 4d

Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data

After Ionis Pharmaceuticals (IONS) and AstraZeneca (AZN) presented full results of the Cardio-TTRansform trial at the ESC Congress 2026 in Munich, Jefferies sai...

Simply Wall St 5d

Why Everyone Is Watching Alnylam Pharmaceuticals Today

Alnylam Pharmaceuticals (ALNY) is back in focus after announcing plans to present fresh clinical and real world data on AMVUTTRA and zilebesiran at the European...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Vertex Pharmaceuticals

Intuitive Surgical

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.